Background and aims: Cirrhotic cardiomiopathy (CC) comprises a constellation of cardiac abnormalities associated with liver cirrhosis (LC) progression and due to multiple pathogenetic mechanisms; even if not responsible of overt heart failure, CC plays a major role in cardiac dysfunction complicating OLT or TIPPS placement. Our work aims at assessing the prevalence of CC and the different role of possible CC-associated factors. Materials and methods: 50 patients (17 f) affected by LC and 17 (6f) by chronic hepatitis were studied. Hemochromatosis, cardiopulmonary or alcohol-related diseases were excluded. All subjects were assessed for cardiac parameters (EF, Ea, TAPSE, E/A ratio and Deceleration time (DT), QTc interval); Child-Pugh score; ANF ,BNF, Epinephrine (E), Norepinephrine (NE), PRA, Aldosterone (A), nitric oxide (NO), IL-6 and TNF-a, PIIINP plasma levels; APRI, Fibroscore, 4-parameter scores; drugs history (type and exposition time). Results: We observed a significant prevalence of diastolic dysfunction in LC group (50% of patients had abnormal E/A ratio and 62% abnormal DT) with a higher prevalence in advanced disease (100% and 92 % of Child C patients had abnormal E/A ratio and DT, respectively). Prolonged QT (pQT) was present in 19 LC patients (38%) vs. 1 (6.25%) in ECA subjects (p<.001). At univariate analysis, diastolic dysfunction indices (abnormal DT and E/A ratio) resulted significantly related to NO, TNF-alfa, NE, E , A , PRA, ANP and BNP plasma levels; they both were also significantly related to plasma PIIINP levels , Fibroscore and 4-parameters fibrosis scores. A significant correlation between pQT interval and Child score, duration of disease (years), plasma levels of TNF-a, A, ANP, BNP, PIIINP and Fibroscore and 4-parameters scores was also present. E/A ratio, DT and pQT resulted significantly inversely related to antialdosterone therapy exposition (measured as AUC of time x dose). The table resumes the multivariate analysis’ results (stepwise multiple logistic regression) using E/A ratio <1 as dependent variable. Similar result were obtained when using pQT as dependent variable.  SE OR 95% CI p Antialdosterone exposition -.539 .137 0.66 0.43-0.78 .011 Child Score .621 .292 1.35 1.26-2.13 .019 Aldosterone .728 .325 1.26 1.15-3.58 .026 PIIINP .345 .121 1.06 1.02-1.18 .042 Conclusions: Antialdosterone exposition results inversely and independentely related to CC abnormalities, this suggesting a role for optimized (in terms of dose and timing) antialdosterone therapy in prevention of CC development.

Antialdosterone therapy in liver cirrhosis: a role for prevention of cirrhitc cardiomiopathy ? / Ventura, Paolo; Ferrari, Mariachiara; Nuzzo, Anna Chiara; Nascimbeni, Fabio; Romagnoli, Elisa; Rossi, Rosario; Moriondo, Valeria; Vegetti, Alberto; Modena, Maria Grazia; Pietrangelo, Antonello. - In: JOURNAL OF HEPATOLOGY. - ISSN 0168-8278. - STAMPA. - 52:(2010), pp. S87-S87. ((Intervento presentato al convegno The International Liver Congress 2010 tenutosi a Vienna (Austria) nel 14-18 aprile 2010.

Antialdosterone therapy in liver cirrhosis: a role for prevention of cirrhitc cardiomiopathy ?

VENTURA, Paolo;FERRARI, Mariachiara;NUZZO, Anna Chiara;NASCIMBENI, Fabio;ROMAGNOLI, Elisa;ROSSI, Rosario;MORIONDO, Valeria;VEGETTI, Alberto;MODENA, Maria Grazia;PIETRANGELO, Antonello
2010

Abstract

Background and aims: Cirrhotic cardiomiopathy (CC) comprises a constellation of cardiac abnormalities associated with liver cirrhosis (LC) progression and due to multiple pathogenetic mechanisms; even if not responsible of overt heart failure, CC plays a major role in cardiac dysfunction complicating OLT or TIPPS placement. Our work aims at assessing the prevalence of CC and the different role of possible CC-associated factors. Materials and methods: 50 patients (17 f) affected by LC and 17 (6f) by chronic hepatitis were studied. Hemochromatosis, cardiopulmonary or alcohol-related diseases were excluded. All subjects were assessed for cardiac parameters (EF, Ea, TAPSE, E/A ratio and Deceleration time (DT), QTc interval); Child-Pugh score; ANF ,BNF, Epinephrine (E), Norepinephrine (NE), PRA, Aldosterone (A), nitric oxide (NO), IL-6 and TNF-a, PIIINP plasma levels; APRI, Fibroscore, 4-parameter scores; drugs history (type and exposition time). Results: We observed a significant prevalence of diastolic dysfunction in LC group (50% of patients had abnormal E/A ratio and 62% abnormal DT) with a higher prevalence in advanced disease (100% and 92 % of Child C patients had abnormal E/A ratio and DT, respectively). Prolonged QT (pQT) was present in 19 LC patients (38%) vs. 1 (6.25%) in ECA subjects (p<.001). At univariate analysis, diastolic dysfunction indices (abnormal DT and E/A ratio) resulted significantly related to NO, TNF-alfa, NE, E , A , PRA, ANP and BNP plasma levels; they both were also significantly related to plasma PIIINP levels , Fibroscore and 4-parameters fibrosis scores. A significant correlation between pQT interval and Child score, duration of disease (years), plasma levels of TNF-a, A, ANP, BNP, PIIINP and Fibroscore and 4-parameters scores was also present. E/A ratio, DT and pQT resulted significantly inversely related to antialdosterone therapy exposition (measured as AUC of time x dose). The table resumes the multivariate analysis’ results (stepwise multiple logistic regression) using E/A ratio <1 as dependent variable. Similar result were obtained when using pQT as dependent variable.  SE OR 95% CI p Antialdosterone exposition -.539 .137 0.66 0.43-0.78 .011 Child Score .621 .292 1.35 1.26-2.13 .019 Aldosterone .728 .325 1.26 1.15-3.58 .026 PIIINP .345 .121 1.06 1.02-1.18 .042 Conclusions: Antialdosterone exposition results inversely and independentely related to CC abnormalities, this suggesting a role for optimized (in terms of dose and timing) antialdosterone therapy in prevention of CC development.
52
S87
S87
Ventura, Paolo; Ferrari, Mariachiara; Nuzzo, Anna Chiara; Nascimbeni, Fabio; Romagnoli, Elisa; Rossi, Rosario; Moriondo, Valeria; Vegetti, Alberto; Modena, Maria Grazia; Pietrangelo, Antonello
Antialdosterone therapy in liver cirrhosis: a role for prevention of cirrhitc cardiomiopathy ? / Ventura, Paolo; Ferrari, Mariachiara; Nuzzo, Anna Chiara; Nascimbeni, Fabio; Romagnoli, Elisa; Rossi, Rosario; Moriondo, Valeria; Vegetti, Alberto; Modena, Maria Grazia; Pietrangelo, Antonello. - In: JOURNAL OF HEPATOLOGY. - ISSN 0168-8278. - STAMPA. - 52:(2010), pp. S87-S87. ((Intervento presentato al convegno The International Liver Congress 2010 tenutosi a Vienna (Austria) nel 14-18 aprile 2010.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/641733
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact